600276.SH
恒瑞医药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 46.76
−2.05%Year over year
Reported trailing growth
- Revenue
- +11.5%
- EBITDA
- —
- EBIT
- +19.8%
- EPS
- +15.3%
- Free cash flow
- +84.3%
- Operating cash flow
- +70.6%
Forward estimates
Based on analyst estimates
- Revenue
- +2.9%
- EBITDA
- +9.5%
- EPS
- +8.4%
Three-year CAGR
- Revenue
- +14.1%
- EBITDA
- +28.0%
- EBIT
- +29.8%
- Net income
- +25.4%
- EPS
- +25.0%
- Free cash flow
- +15.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026